Otsu Hajime, Oki Eiji, Ikawa-Yoshida Ayae, Kawano Hiroyuki, Ando Koji, Ida Satoshi, Kimura Yasue, Aishima Shinichi, Saeki Hiroshi, Morita Masaru, Kohnoe Shunji, Oda Yoshinao, Maehara Yoshihiko
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan Chugai Research Institute for Medical Science, Inc., Shizuoka, Japan.
Anticancer Res. 2015 Apr;35(4):2441-6.
Results from the Trastuzumab for Gastric Cancer (ToGA) trial highlighted the clinical significance of trastuzumab in the treatment of HER2 (Human Epidermal Growth Factor Receptor type 2)-positive gastric cancer. However, whether expression of HER2 is related to prognosis of gastric cancer is still controversial. A total of 360 consecutive patients with gastric cancer who underwent surgical resection in our Department from 1994 to 2007 were analyzed. We performed immunohistochemical analysis of HER2 expression. HER2 expression level was classified into four scores (0, 1+, 2+ and 3+). There were 37 (10%) patients with a score of 3+. A score of 3+ was defined as being HER2-positive. Recurrence-free survival was worse in HER2-positive cases (p=0.045). When the analysis was conducted with intestinal types of cancer, RFS was considerably worse in the HER2-positive group (p=0.011). HER2 expression may have potential as a prognostic factor for intestinal cancer types. Further research is warranted.
曲妥珠单抗治疗胃癌（ToGA）试验的结果突出了曲妥珠单抗在治疗人表皮生长因子受体2（HER2）阳性胃癌中的临床意义。然而，HER2的表达是否与胃癌预后相关仍存在争议。对1994年至2007年在我科接受手术切除的360例连续性胃癌患者进行了分析。我们对HER2表达进行了免疫组化分析。HER2表达水平分为四个评分（0、1+、2+和3+）。有37例（10%）患者评分为3+。评分为3+被定义为HER2阳性。HER2阳性病例的无复发生存期较差（p=0.045）。当对肠型癌症进行分析时，HER2阳性组的无复发生存期明显较差（p=0.011）。HER2表达可能具有作为肠型癌症预后因素的潜力。有必要进行进一步的研究。
Zotero 插件